Venlafaxine to prevent postherpetic neuralgia after shingles

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional trial will compare venlafaxine plus conventional therapy versus conventional therapy alone in adults with recent-onset shingles and moderate to severe pain (NRS ≥4). Eligible participants must have rash onset within 30 days and adequate liver and kidney function, while patients with head/neck/ocular involvement, major depressive disorder requiring antidepressants, known venlafaxine hypersensitivity, or certain immune or cancer conditions are excluded. Participants will receive assigned treatment and be followed for pain outcomes and safety measures to determine whether venlafaxine prevents the transition to chronic postherpetic neuralgia. The study is conducted at Beijing Tiantan Hospital with collaborating centers listed by the sponsor.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 1\. Ages more than 18 years;
* 2\. Patients with onset of HZ rash less than 30 days;
* 3\. Experiencing moderate to severe HZ pain with an average pain score of at least 4 on a Numeric Rating Scale (NRS, 0 = no pain, 10 = worst possible pain);
* 4\. Aspartate aminotransferase and alanine aminotransferase levels less than twice the upper limit of normal;
* 5\. Estimated glomerular filtration rate of 30 mL/min per 1.73 m2 or higher;
* 6\. Willing to sign the informed consent form and possessing sufficient cognitive and language abilities to comply with all the study requirements.

Exclusion Criteria:

* 1\. HZ with head, neck, ocular, mucous membrane, cranial nerve, or central nervous system involvement or generalized HZ;
* 2.Known hypersensitivity to venlafaxine;
* 3\. Previous antiviral treatment that did not comply with guideline recommendations;
* 4\. History of herpes zoster vaccination before enrollment;
* 5.History of major depressive disorder requiring antidepressant therapy;
* 6.History of systemic immune diseases, organ transplantation, or cancers;
* 7.Pregnancy or lactation;
* 8.Presence of acute or chronic pain disorders other than HZ.

Where it's running

• Beijing Tiantan Hospital, Beijing, Beijing 100070
  Beijing, China Recruiting

Study contacts

• Study coordinator: Fang Luo
• Email: 13611326978@163.com
• Phone: 13611326978

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Erector spinae plane block versus transcutaneous radiofrequency for postherpetic neuralgia

  This project will see if erector spinae plane block or transcutaneous radiofrequency works better to reduce pain in adults with postherpetic neuralgia.

  Recruiting Diskapi Teaching and Research Hospital · Ankara · NCT07400640

• Recombinant Zoster Vaccine with ZFA01 Adjuvant in Adults 40+

  A two-part study tests a recombinant herpes zoster vaccine in healthy adults aged 40 and older to see if it boosts immune responses and is safe.

  Recruiting at 2 sites Phase 1/2 Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. · Guangxi, Nanning and 1 other locations · NCT07920172

• How long the live shingles vaccine protects you

  This will see if the live attenuated shingles vaccine keeps adults from the original Phase III trial protected against herpes zoster for up to six years after vaccination.

  Recruiting Jiangsu Province Centers for Disease Control and Prevention · Nanjing, Jiangsu · NCT07585370

• Recombinant zoster (Shingrix) to see if it lowers new dementia diagnoses in people 76 and older in Finland.

  This trial will test whether the Shingrix shingles vaccine lowers the chance of a new dementia diagnosis in people aged 76 or older who live in Finland.

  Recruiting at 8 sites Phase 4 GlaxoSmithKline · Espoo and 7 other locations · NCT07502560

• Lyophilized shingles mRNA vaccine safety and immune response

  This trial will test a lyophilized mRNA vaccine to see if it is safe and produces immune responses in adults aged 40 years and older.

  Recruiting Phase 1/2 Sinovac Biotech Co., Ltd · Xinjiang · NCT07400003

• Transcutaneous pulsed radiofrequency for postherpetic neuralgia pain

  This study will try a non-invasive pulsed radiofrequency treatment applied through the skin to reduce pain in adults with postherpetic neuralgia who have not responded to standard treatments.

  Recruiting Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization · Istanbul, Istanbul · NCT07390279

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.